Center for Population Health Research, National Institute of Public Health, Cuernavaca, Mexico.
Wolfson Institute of Preventive Medicine Centre for Cancer Prevention, Queen Mary University, London, United Kingdom.
JAMA Netw Open. 2019 Nov 1;2(11):e1915781. doi: 10.1001/jamanetworkopen.2019.15781.
Triage tests enhance the efficiency cervical cancer screening based on human papillomavirus (HPV), but the best approach for maximizing programmatic effectiveness is still uncertain, particularly in a real-world scenario.
To compare the clinical performance of 6 triage strategies based on liquid-based cytology (LBC) and HPV-16 and HPV-18 genotyping individually or in combination as sequential triage tests to detect cervical intraepithelial neoplasia (CIN) grade 2 or higher among women with high-risk HPV.
DESIGN, SETTING, AND PARTICIPANTS: This diagnostic study of routine cervical cancer screening was conducted at 100 primary health centers in Tlaxcala, Mexico. Women aged 30 to 64 years were recruited from August 1, 2013, to February 24, 2016, as part of the Forwarding Research for Improved Detection and Access for Cervical Cancer Screening and Triage study. Six triage scenarios for referral to colposcopy were examined: (1) LBC testing that found atypical squamous cells of undetermined significance (ASC-US) or worse, (2) positive results in HPV-16 genotyping, (3) positive results in HPV-18 genotyping, (4) positive results in HPV-16/HPV-18 genotyping, (5) positive results in HPV-16 genotyping or, if genotyping results were negative, reflex LBC testing that found ASC-US or worse, and (6) positive results in HPV-16/HPV-18 genotyping or, if genotyping results were negative, reflex LBC testing that found ASC-US or worse. Data were analyzed from October 2017 to August 2018.
Liquid-based cytological testing with simultaneous HPV-16 and HPV-18 genotyping. Women whose HPV genotyping results were positive for HPV-16 or HPV-18 or whose LBC results found ASC-US or worse and a random set of negative and normal results were referred to colposcopy with histologic analysis used for disease confirmation.
Clinical performance of each test strategy for detection of CIN grade 2 or higher. Secondary outcomes included resource utilization of each triage scenario, measured by the number of tests performed, the referral rate for colposcopy, and the numbers of colposcopies per CIN grade 2 or higher detected.
A total of 36 212 women (median [interquartile range] age, 40 [35-47] years) were screened, and 4051 women (11.2%) had high-risk HPV. Of these women, 1109 (24.6%) were found to have HPV-16, HPV-18, or ASC-US or worse. Further histologic testing detected CIN grade 2 or higher in 110 of 788 women (14.0%) who underwent follow-up colposcopy. Sensitivity and specificity for 3 main triage strategies were 42.9% and 74.0% for LBC; 58.3% and 54.4% for HPV-16/HPV-18 genotyping; and 86.6% and 34.0% for HPV-16/HPV-18 genotyping with reflex LBC. The referral rate to colposcopy was 29% for HPV-16/HPV-18 with reflex LBC, which was 2-fold higher than the referral rate of 12% for LBC.
Triage of women with high-risk HPV with HPV-16/HPV-18 genotyping with reflex LBC was significantly associated with improvement in detection of CIN grade 2 or higher compared with LBC alone. The benefit of disease prevented may outweigh the cost of increasing requirements for colposcopy services in settings with limited adherence to follow-up after a positive screening result.
基于人乳头瘤病毒(HPV)的宫颈癌筛查中,分流检测可提高效率,但在实际情况下,如何最大限度地提高项目效果仍不确定。
比较 6 种基于液基细胞学(LBC)和 HPV-16、HPV-18 基因分型的单独或联合作为连续分流检测,用于检测高危 HPV 女性的宫颈上皮内瘤变(CIN)2 级或更高病变的临床性能。
设计、设置和参与者:本项关于常规宫颈癌筛查的诊断研究在墨西哥特拉斯卡拉州的 100 个初级保健中心进行。2013 年 8 月 1 日至 2016 年 2 月 24 日期间,招募了年龄在 30 至 64 岁之间的女性,作为前瞻性研究以提高宫颈癌筛查和分流检测的研究的一部分。共研究了 6 种转介行阴道镜检查的分流方案:(1)LBC 检测发现非典型鳞状细胞意义不明确(ASC-US)或更高级别病变;(2)HPV-16 基因分型阳性;(3)HPV-18 基因分型阳性;(4)HPV-16/HPV-18 基因分型阳性;(5)HPV-16 基因分型阳性,如基因分型结果为阴性,则进行 LBC 检测发现 ASC-US 或更高级别病变;(6)HPV-16/HPV-18 基因分型阳性,如基因分型结果为阴性,则进行 LBC 检测发现 ASC-US 或更高级别病变。数据分析于 2017 年 10 月至 2018 年 8 月进行。
同时进行 HPV-16 和 HPV-18 基因分型的液基细胞学检测。HPV 基因分型阳性 HPV-16 或 HPV-18 或 LBC 结果发现 ASC-US 或更高级别病变的女性,以及随机选取的阴性和正常结果的女性,均转介行阴道镜检查,采用组织学分析进行疾病确诊。
各检测策略检测 CIN 2 级或更高级别病变的临床性能。次要结局包括各分流方案的资源利用情况,通过检测次数、阴道镜检查转诊率以及每例 CIN 2 级或更高级别病变检出的阴道镜检查次数进行衡量。
共对 36212 名女性(中位数[四分位数间距]年龄,40 [35-47] 岁)进行了筛查,其中 4051 名女性(11.2%)为高危 HPV 阳性。这些女性中,1109 名(24.6%)女性 HPV-16、HPV-18 或 ASC-US 或更高级别病变。进一步的组织学检查发现,1109 名接受随访阴道镜检查的女性中有 110 名(14.0%)患有 CIN 2 级或更高级别病变。3 种主要分流策略的敏感性和特异性分别为:LBC 为 42.9%和 74.0%;HPV-16/HPV-18 基因分型为 58.3%和 54.4%;HPV-16/HPV-18 基因分型联合 LBC 为 86.6%和 34.0%。HPV-16/HPV-18 基因分型联合 LBC 的阴道镜检查转诊率为 29%,比 LBC 的 12%高出 2 倍。
与单独使用 LBC 相比,高危 HPV 女性使用 HPV-16/HPV-18 基因分型联合 LBC 分流,可显著提高 CIN 2 级或更高级别病变的检出率。在遵循阳性筛查结果后随访率有限的情况下,预防疾病的益处可能超过增加阴道镜检查服务需求的成本。